Table 2.
Pretransplant treatment and CV characteristics
| Variable | N (%)* |
|---|---|
|
| |
| PreHCT anthracycline | |
| Yes | 482 (73) |
| No | 175 (27) |
| Unknown | 4 (<1) |
| Median anthracycline dose, mg/m2 (range) | 112 (7-634) |
|
| |
| PreHCT cranial radiation | |
| Yes | 118 (19) |
| No | 504 (81) |
| Unknown | 39 (6) |
| Median cranial radiation dose, cGy (range) | 1200 (12-5040) |
|
| |
| PreHCT chest radiation | |
| Yes | 86 (14) |
| No | 540 (86) |
| Unknown | 35 (5) |
| Median chest radiation dose, cGy (range) | 700 (10-5040) |
|
| |
| Hypertension | |
| Yes | 25 (4) |
| No | 576 (96) |
| Unknown | 60 (9) |
|
| |
| Diabetes or hyperglycemia | |
| Yes | 14 (2) |
| No | 604 (98) |
| Unknown | 43 (7) |
|
| |
| Triglycerides >150 mg/dl | |
| Yes | 91 (24) |
| No | 292 (76) |
| Missing | 278 (42) |
|
| |
| HDL cholesterol <40 mg/dl | |
| Yes | 4 (3) |
| No | 151 (97) |
| Missing | 506 (77) |
|
| |
| LDL cholesterol >130 mg/dl | |
| Yes | 3 (2) |
| No | 151 (98) |
| Missing | 507 (77) |
|
| |
| Cardiomyopathy | |
| Yes | 10 (2) |
| No | 629 (98) |
| Not assessed | 22 (3) |
|
| |
| Cardiac structural defect at diagnosis | |
| Yes | 29 (4) |
| No | 628 (96) |
| Missing | 4 (<1) |
|
| |
| CAD/myocardial infarction | |
| Yes | 1 (<1) |
| No | 632 (99) |
| Missing | 28 (4) |
HDL= high-density lipoprotein, LDL= low-density lipoprotein, CAD= coronary artery disease
*
Percentages reported for the categories “unknown” and “missing” reflect the entire population, n=661. The percentages reported for all other variables are based on the available data and excludes the number of subjects with missing data.